Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer

Cited by (318)

Items 301–318 of 318

1. Additional file 3 of Optimization of SPECT/CT imaging protocols for quantitative and qualitative 99mTc SPECT
   Dennis Kupitz, Heiko Wissel, Jan Wuestemann, Stephanie Bluemel, Maciej Pech, Amthauer, Holger, Michael Christoph Kreissl, Oliver S. Großer · 2021 · Figshare
2. Additional file 1 of Organ and tumor dosimetry including method simplification for [177Lu]Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer
   Amir Karimzadeh, Schatz, Linus, Markus Sauer, Ivayla Ilieva Apostolova, Ralph Buchert, Susanne Klutmann, Wencke Lehnert · 2024 · Figshare
3. Additional file 1 of Optimization of SPECT/CT imaging protocols for quantitative and qualitative 99mTc SPECT
   Dennis Kupitz, Heiko Wissel, Jan Wuestemann, Stephanie Bluemel, Maciej Pech, Amthauer, Holger, Michael Christoph Kreissl, Oliver S. Großer · 2021 · Figshare
4. Additional file 1 of Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial)
   Esmée C. A. van der Sar, Arthur J. A. T. Braat, Jochem R.N. van der Voort van Zyp, Betty S. van der Veen, van Leeuwen, Pim J., Daphne M. V. de Vries–Huizing, Hendrikx, Jeroen M. A., Marnix G. E. H. Lam, Wouter V. Vogel · 2023 · Figshare
5. Chromatin Nano-Organization in Peripheral Blood Mononuclear Cells After In-Solution Irradiation with the Beta-Emitter Lu-177
   Myriam Schäfer, Razan Muhtadi, Sarah Schumann, Felix Bestvater, Uta Eberlein, Georg Lars Hildenbrand, Harry Scherthan, Michael Hausmann · 2026 · Biomolecules
6. Recommendations for the dosimetry of patients undergoing therapy with radiopharmaceuticals that include 177Lu
   Pablo Mínguez Gabiña, Nuria Carrasco Vela, L. Irazola Rosales, Josep María Martí-Climent, Luis Carlos Martínez Gómez, Teresa Monserrat Fuertes, Carlos Montes Fuentes, Alfredo Montes Uruen, Raquel Barquero Sanz · 2026 · Physica Medica
7. Dosimetric analysis reveals rapid clearance and low absorbed dose of [¹⁷⁷Lu]Lu-PSMA-617 in non-prostate cancers with high PSMA expression
   Fadi Khreish, Florian Rosar, Caroline Burgard, Sven Petto, Stephan Maus, Tobias Stemler, Mark Daniel Bartholomä, Amir Sabet, Andrea Schaefer-Schuler, Samer Ezziddin · 2026 · EJNMMI Research
8. Renal and Hematologic Toxicity Profile of [177] Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT): A Retrospective Cohort Study
   Merve Yalçınkaya, Fadime Demir, S. Karaçavuş, M. Demir · 2026 · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
9. RETRACTED: Assessment of whole-body radiation exposure to technologists during manual preparation of high specific activity non-carrier added 177Lu radiolabeled pharmaceuticals
   Sudha Murthy, G.J. Naga Raju · 2026 · EPJ Web of Conferences · Retracted
10. Perfil de toxicidad renal y hematológica de la terapia con radioligandos dirigida al PSMA marcada con 177Lu (177Lu-PSMA-RLT): estudio de cohorte retrospectivo
    Merve Yalçınkaya, F. Demir, Seyhan Karaçavuş, M. Demir · 2026 · Revista Española de Medicina Nuclear e Imagen Molecular
11. Long-term quality control of manually prepared [177Lu]Lu-labeled radiopharmaceuticals in routine clinical practice
    Emre Karayel, Aslan Aygün, Hüseyin Pehlivanoğlu · 2026 · Journal of Radioanalytical and Nuclear Chemistry
12. Hemoglobin-Based Oxygen Carriers Promoted the Antitumor Effect of 177 Lu-PSMA-617 by Enhancing DNA Repair Capacity of Immune Cells
    Danyue Qu, Chenyi Shao, Xinyuan Ji, Yichi Huang, Tian Chen, Li J, Hu Zhou, Yilei Shi, Hong Wang, J Y Liu et al. · 2026 · Cancer Biotherapy and Radiopharmaceuticals
13. Publication trends and knowledge structure of prostate-specific membrane antigen radioligand therapy for prostate cancer: a bibliometric analysis, 2015–2025
    Hao Long, Xu-Hua Qiao, X J Li, Xiangjun Kong, Qin-Wen Liu · 2026 · Nuclear Medicine Communications
14. Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapy: dosimetry results
    Josef Zahner, Astrid Delker, Zachary Ells, Ana Antic Nikolic, Adrien Holzgreve, Sophie C. Siegmund, Maximilian Tiling, Mathias Johannes Zacherl, Elena Katharina Berg, Can Daniel Aydogdu et al. · 2026 · European Journal of Nuclear Medicine and Molecular Imaging
15. Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry
    Sophie Carina Kunte, Astrid Delker, Liam Widjaja, Johannes Hornfeck, M X Wu, Lena Maria Unterrainer, Franz Josef Gildehaus, Guido Böning, Rudolf A. Werner, Zachary Ells · 2026 · European Journal of Nuclear Medicine and Molecular Imaging
16. Recent advances in nuclear medicine for cancer diagnosis and targeted therapy
    Emmanuel O. Oisakede, Odunola Fridauz Atitebi, Doyin Blessing Bamidele, Euphemia Murateng Matope, John Oluwatosin Alabi, David B. Olawade · 2026 · Cancer Bioscience
17. Influence of increased injected activities up 9.0 GBq [177Lu]Lu-PSMA-I&T on absorbed doses to lesions and kidneys
    Zachary Ells, Linus Hempel, Julia Ells, Muyu Wu, Maximilian Scheifele, Magdalena Schöll, Sophie C. Siegmund, Mathias Zacherl, Rudolf A. Werner, Jérémie Calais et al. · 2026 · EJNMMI Physics
18. ACP3 Theranostics in Prostate Cancer
    Zhilin Luo, Danlei Chen, Tianyi Ma, Pingping Zeng, Xuejie Li, Haoyuan Shi, Zhiyuan Hu · 2026 · Cancers